Processing

Please wait...

Settings

Settings

Goto Application

1. JP2012006953 - TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II

Office
Japan
Application Number 2011173569
Application Date 09.08.2011
Publication Number 2012006953
Publication Date 12.01.2012
Publication Kind A
IPC
A61K 38/46
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
A61J 1/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
1Containers specially adapted for medical or pharmaceutical purposes
05for collecting, storing or administering blood, plasma or medical fluids
14Details; Accessories therefor
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 38/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
47acting on glycosyl compounds (3.2), e.g. cellulases, lactases
C12Y 302/0102
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
YENZYMES
302Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
0102Alpha-glucosidase (3.2.1.20)
A61P 21/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21Drugs for disorders of the muscular or neuromuscular system
A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
A61P 37/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
Applicants DUKE UNIV
デューク ユニバーシティ
Inventors CHEN YUAN-TSONG
チェン,ユアン-ツォン
Agents 小野 新次郎
小林 泰
千葉 昭男
富田 博行
泉谷 玲子
Priority Data 60/219,237 18.07.2000 US
Title
(EN) TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II
(JA) II型糖原病の治療
Abstract
(EN)

PROBLEM TO BE SOLVED: To provide a composition for use in treatment of glycogen storage disease type II.

SOLUTION: There is provided a pharmaceutical composition comprising human acid α-glucosidase in a container with a label containing instructions for administration of the composition for treatment of glycogen storage disease type II. The human acid α-glucosidase is preferably recombinant human acid α-glucosidase, further preferably a precursor of recombinant human acid α-glucosidase. Further more preferably, the precursor of recombinant human acid α-glucosidase is produced in Chinese hamster ovary cells. The human acid α-glucosidase is administered at the regular interval (for example, monthly, bimonthly, weekly, twice weekly, daily). In a preferred embodiment, the human acid α-glucosidase is administered intravenously, intramuscularly, intrathecally or intraventricularly.

COPYRIGHT: (C)2012,JPO&INPIT


(JA)

【課題】II型糖原病を有する個体を治療するための医薬組成物の提供。
【解決手段】II型糖原病の治療用組成物の投与のための指示書を含むラベルを有する容器内に、ヒト酸α−グルコシダーゼを含有する医薬組成物。該ヒト酸α−グリコシダーゼは、好ましくは組換えヒト酸α−グリコシダーゼ、より好ましくはヒト酸α−グリコシダーゼの前駆体形態、およびさらにより好ましくはチャイニーズハムスター卵巣細胞において産生されるヒト酸α−グリコシダーゼの前駆体形態である。該ヒト酸α−グリコシダーゼは、周期的(例えば、毎月、月に2回、毎週、週に2回、毎日)に投与される。好ましい態様では、該ヒト酸α−グリコシダーゼは、静脈内;筋肉内;髄腔内;または脳室内に投与される。
【選択図】なし